News & Updates

A cross-sectional institutional study has found low understanding of oral anticancer medication (OAM) use and handling among vulnerable patients, which does not align with patient-reported adherence.

The oral selective JAK1/2 inhibitor baricitinib significantly reduces the risk of death in critically ill COVID-19 patients who are on invasive mechanical ventilation (IMV) or ECMO*, when used in combination with standard care, according to the addendum study of the COV-BARRIER trial presented at IDWeek 2021.

A recent study has shown the safety and feasibility of routine outpatient administration of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH), with a positive annual impact on margin amounting to $1,444,548 at a comprehensive cancer centre.

Overall survival (OS) is similar between patients with and without renal insufficiency who have been treated with erlotinib, reports a study. Progression-free survival (PFS) is about 6 months shorter in PFS patients with classical mutation relative to those with RI, albeit statistically nonsignificant.

Individual- and community-level factors, such as age and travel distance to the clinic, among others, exert influence on the completion of human papillomavirus two-dose vaccine series among adolescents, according to a study.

The gonadotropin-releasing hormone (GnRH) antagonist degarelix and the GnRH agonist leuprolide appear to be similar in terms of the rate of cardiovascular events in a cohort of patients with prostate cancer, according to the results of the PRONOUNCE trial.